RE:RE:RE:come ontruestar2 wrote:
I agree that CGC will make a move upwards and cross the 2BB Market Cap - perhaps next week. Where ACB has the edge is that they have more approved space, 650K sq feet, and that space is all under one roof, not spread across 4 locations, which allows for efficiency of scale based savings on staff, management, grow timing, shipping, etc.. ACB also owns Canvas RX, the leader in Medical sign ups, and can manipulate these sign ups according to their grow patterns - overall they are both going to go a lot higher, but ACB may have more multiple left in it due to current valuations
It isn't just that. ACB gets their water from the mountains for free, and does not have nearly as much overhead as CGC. They have half of the patients as CGC but growing faster than any before it because they price all of their strains at $8. In other words, you can get high THC for cheap when especially when compared with Tweed and Tilray. They have the most high-tech facility in the works which should drop their costs not even considering the scale. I think that this facility will serve Canada and they must be trying to join with foreign companies. There is a lot to come for this industry. Even without rec sales this company has done great, especially when compared with companies like CGC. Rec sales is the icing on the cake, and I think that some of these companies will eventually make the cigarette companies look like small caps in comparison. They are priced in the $140 billion dollar range. If cigarettes take that much of the cake with only one product, I cannot even imagine what the street will award companies like Aurora.